Effect of Immune No. 2 (2) on the immune reconstitution in patients with HIV/AIDS after highly active antiretroviral treatment: A randomized double blind placebo controlled clinical trial

Chinese Journal of Integrative Medicine

Volumn 19, Issue 5, 2013, Pages 340-346

  Wang, Jie ^a   Li, Yong ^a   Tang, Yan Li ^a   Lin, Hong Sheng ^a   Wu, Xin Fang ^a   Liu, Jie ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

HIV AIDS; Immune No. 2; immune reconstitution

Indexed keywords

CD45RA ANTIGEN; CD45RO ANTIGEN; CHINESE DRUG; IMMUNE NO 2; LAMIVUDINE; NEVIRAPINE; PLACEBO; UNCLASSIFIED DRUG; ZIDOVUDINE;

ABDOMINAL DISTENSION; ABSENCE OF SIDE EFFECTS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTHRALGIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CHINESE MEDICINE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DYSPNEA; FATIGUE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOCOMPETENT CELL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OPHIOCORDYCEPS; PANAX QUINQUEFOLIUS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIGENS, CD45; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MALE; PLACEBOS; VIRAL LOAD;

EID: 84878334621     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-013-1449-z     Document Type: Article

References (14)

1. Corbeau P, Reynes J. Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood 2011;117:5582-5590.
2. Renaud M, Katlama C, Mallet A, Calvez V, Carcelain G, Tubiana R, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 1999;13:669-676.
3. Ministry of Health of the People's Republic of China. The national HIV testing technology standard. Beijing: Chinese Center for Disease Control and Prevention;2009:5-18.
4. Zheng XY, ed. Guiding principle of Clinical researches on new drugs of traditional Chinese medicine. Beijing: China Medical Science Press;2002:28-31.
5. Wang YH, Liu Zhong S, Guan F, Wang R. Research on immunological regulation effect of Radix Panacis Quinquefolii and related preparation. Chin Arch Tradit Chin Med (Chin) 2004;22:566-567.
6. Zhang X, Li S. Progress on research of Chinese medicine in the treatment of AIDS. Chin J Inf TCM (Chin) 2000;7:20-22.
7. Guo HC, Gao JQ, Xi QY, Li XH. Progress of research of Sphaeria sinensis. J Microbiol (Chin) 2003;23:50-55.
8. Li TS, Carcelaine G, Debre P, Autran B. Immune reconstitution in AIDS patients during highly active antiretroviral therapies. Basic Med Sci Clin (Chin) 2001;21:6-11.
9. Benveniste O, Flahault A, Rollot F, Elbim C, Estaquier J, Pédron B, et al. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis 2005;191:1670-1679.
10. Marziali M, De Santis W, Carello R, Leti W, Esposito A, Isgrò A, et al. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART. AIDS 2006;20:2033-2041.
11. Isgrò A, Leti W, De Santis W, Marziali M, Esposito A, Fimiani C, et al. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART. Clin Infect Dis 2008;46:1902-1910.
12. Smith KY, Valdez H, Landay A, Spritzler J, Kessler HA, Connick E, et al. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J Infect Dis 2000;181:141-147.
13. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4 + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116.
14. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry-patient-reported outcome measures: use in medical product development to support labeling claims, draft guidance. Health Qual Life 2006;4:79.